1
|
Chauvet P, Moisan R, Mongbo S, Naban S, Abou-Chahla W, Nelken B, Barbati M, Duployez N, Podvin B, Dubois R, Bruno B. Philadelphia chromosome-positive B-cell lymphoblastic lymphoma in a child: Case report and literature review. Pediatr Blood Cancer 2024; 71:e30884. [PMID: 38265257 DOI: 10.1002/pbc.30884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Accepted: 01/10/2024] [Indexed: 01/25/2024]
Affiliation(s)
- Paul Chauvet
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
- CHU de Lille, Maladies du Sang, Université de Lille, Lille, France
| | - Rafael Moisan
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
| | - Sarah Mongbo
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
| | - Soumeya Naban
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
| | - Wadih Abou-Chahla
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
| | - Brigitte Nelken
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
| | - Melissa Barbati
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
| | - Nicolas Duployez
- CHU de Lille, Service d'hématologie biologique, Université de Lille, Lille, France
| | - Benjamin Podvin
- CHU de Lille, Service d'hématologie biologique, Université de Lille, Lille, France
| | - Romain Dubois
- CHU de Lille, Service d'Anatomo-pathologie, Université de Lille, Lille, France
| | - Bénédicte Bruno
- CHU de Lille, Service d'hématologie pédiatrique, Université de Lille, Lille, France
| |
Collapse
|
2
|
Yu Q, Wang G, Wang J, Zhang W, Meng L, Cao Y. Primary Testicular and Cutaneous Philadelphia Chromosome Positive B-Cell Lymphoblastic Lymphoma: A Rare Case and Review. Cancer Manag Res 2022; 14:1507-1514. [PMID: 35478711 PMCID: PMC9038153 DOI: 10.2147/cmar.s353022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 04/04/2022] [Indexed: 11/28/2022] Open
Abstract
Philadelphia chromosome positive B cell lymphoblastic lymphoma (Ph+ B-LBL) is an extremely rare disease. We report a 27-year-old patient diagnosed with primary testicular and cutaneous Ph+ B-LBL without bone marrow involvement. The CCCG-LBL-2016 regimen (https://clinicaltrials.gov/ct2/show/NCT02845882) was initially administered due to the fast pathological diagnosis as B-LBL that was first obtained. To identify potential therapeutic targets, RNA sequencing (RNAseq) was also performed on lymph node specimens as a part of the routine diagnostic workup in our center. Unexpectedly, IKZF1 deletions and BCR-ABL1 fusion transcripts were detected. Based on these results, we retrospectively performed fluorescence in situ hybridization (FISH) for BCR/ABL1 rearrangements in the same lymph node specimen, and a 70% positive signal was detected. The patient subsequently received the CCCG-LBL-2016 protocol combined with the BCR-ABL tyrosine kinase inhibitor (TKI) dasatinib, along with prophylactic intrathecal infusion. Then, the patient underwent TBI-based haploidentical (haplo) allogeneic hematopoietic stem cell transplantation (haplo-allo-HSCT) as consolidation following the achievement of remission and continued taking dasatinib as maintenance therapy. The patient was still in complete remission 1 year after diagnosis. This case indicates that the detection of potential molecular targets, especially those targets that can be pharmacologically treated, such as BCR/ABL1 fusion transcripts, is of important value to both LBL diagnosis and therapeutic strategy choices. FISH, reverse transcriptase polymerase chain reaction (RT-PCR) and/or RNAseq should be routinely carried out in lymphoma specimens to depict its genetic landscape for the further execution of a precise therapy strategy. ![]()
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/GRnU8ppzX9w
Collapse
Affiliation(s)
- Qiuxia Yu
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People’s Republic of China
| | - Gaoxiang Wang
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People’s Republic of China
| | - Jue Wang
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People’s Republic of China
| | - Wei Zhang
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People’s Republic of China
| | - Li Meng
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People’s Republic of China
| | - Yang Cao
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People’s Republic of China
- Correspondence: Yang Cao, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, Hubei, 430030, People’s Republic of China, Tel +86 2783662680, Fax +86 2783662680, Email
| |
Collapse
|